[{"orgOrder":0,"company":"NOVOS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Carbohydrate","year":"2024","type":"Inapplicable","leadProduct":"Trehalose","moa":"||TFEB","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"NOVOS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Gum, Chewing","sponsorNew":"NOVOS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NOVOS \/ Undisclosed"},{"orgOrder":0,"company":"Natural Immune Systems Inc","sponsor":"JBSL-USA Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Enzyme","year":"2016","type":"Inapplicable","leadProduct":"Nattokinase","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Natural Immune Systems Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Natural Immune Systems Inc \/ JBSL-USA Incorporated","highestDevelopmentStatusID":"11","companyTruncated":"Natural Immune Systems Inc \/ JBSL-USA Incorporated"}]

Find Clinical Drug Pipeline Developments & Deals for Nattokinase

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AIChE Annual Meeting
                          Not Confirmed
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Novos vital is a groundbreaking supplement chew scientifically formulated with an ingredient blend shown to support and optimize essential organ functions that decline with age.

                          Product Name : Novos Vital

                          Product Type : Carbohydrate

                          Upfront Cash : Inapplicable

                          February 21, 2024

                          Lead Product(s) : Trehalose,Nattokinase,Rutin

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Natural Immune Systems Inc

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Natural Immune Systems Inc

                          Country arrow
                          AIChE Annual Meeting
                          Not Confirmed

                          Details : Nattokinase is a Enzyme drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypertension.

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          September 01, 2016

                          Lead Product(s) : Nattokinase

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase IV

                          Sponsor : JBSL-USA Incorporated

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank